New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.

New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.

<h4>Background</h4>One of the first clinical observations of ibrutinib activity in the treatment of chronic lymphocytic leukemia (CLL) is a rapid decline in lymph nodes size. This phenomenon is accompanied by an hyperlymphocytosis, either transient or prolonged, which is associated with...

Full description

Bibliographic Details
Main Authors: Sarah Cadot, Chloe Audebert, Charlotte Dion, Soleakhena Ken, Loic Dupré, Laetitia Largeaud, Camille Laurent, Loic Ysebaert, Fabien Crauste, Anne Quillet-Mary
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-07-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1004430

Internet

https://doi.org/10.1371/journal.pmed.1004430

Similar Items